ArticleEuropean journal of nuclear medicine and molecular imaging2025
CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies.
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bimodal nanobody agents for cancer imaging and potential intraoperative guidance: a systematic review.Journal of nanobiotechnology · 2026Pooled it
- Dual-tracer PET/CT with [European journal of nuclear medicine and molecular imaging · 2026Trial
- A single-arm prospective phase I trial of 68Ga-PFBC01 PET/CT for multiple myeloma B cell maturation antigen imaging.The Journal of clinical investigation · 2026Article
- ICOS-Targeted Peptide Imaging Informs Therapeutic Response of STING Agonist in Lung Adenocarcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Article
- On-Resin DIAMSAR-Conjugated CD38-Targeted Peptides and Their Inverso and Dimeric-Inverso Analogs for PET Imaging of Multiple Myeloma.Bioconjugate chemistry · 2026Article
- Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions.MedComm · 2026Review
- Radioligand-Antibody Conjugates: Integrating Antibody Engineering, Chelator Chemistry, and Radioligands for Precision Theranosis.Molecular diagnosis & therapy · 2026Review
- Affinity- and Format-Dependent Pharmacokinetics ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Nanomedicine-Empowered CAR-T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy.International journal of nanomedicine · 2026Review
- Rapid and specific immunoPET imaging of Nectin-4 in gastric cancer and non-small cell lung cancer using [European journal of nuclear medicine and molecular imaging · 2025Article
- ImmunoPET imaging of c-Met using a nanobody-based tracer [European journal of nuclear medicine and molecular imaging · 2025Article
- Noninvasive Evaluation of Trop2 Expression UsingMolecular pharmaceutics · 2025Article
- B-cell maturation antigen targeted PET/CT imaging in multiple myeloma: a first-in-human study.Journal of hematology & oncology · 2025Article
- Noninvasive ImmunoPET imaging of PD-L1 expression in non-small cell lung cancer and bladder cancer using [Colloids and surfaces. A, Physicochemical and engineering aspects · 2025Article
- Incidental finding of subclinical cardiac involvement by [European journal of nuclear medicine and molecular imaging · 2025Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Distinguishing benign lesions from malignant ones using FAPI-based tracers: will we need to bid farewell to dual-time points imaging?European journal of nuclear medicine and molecular imaging · 2025Article
- A zirconium-89-labeled antibody-drug conjugate PET probe for noninvasive monitoring of Nectin4 expression in breast cancer and lung cancer.Cell reports. Physical science · 2025Article
- Technetium-99m-Labeled Fibroblast Activation Protein-Targeted Nanobody Radiotracer: from Preclinical Development to Clinical Translation in Cancer Imaging.ACS pharmacology & translational science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeCD38 is a glycoprotein highly specific to multiple myeloma (MM). Therapeutics using antibodies targeting CD38 have shown promising efficacy. However, the efficient stratification of patients who may benefit from daratumumab (Dara) therapy and timely monitoring of therapeutic responses remain significant clinical challenges. To address these issues, we developed a novel nanobody-based PET tracer, [ MATERIALS AND
methodsWe prepared a new PET imaging probe based on a CD38-targeted nanobody CD3813, [
resultsTOHP-CD3813 retained a high affinity for CD38 with a KD of 0.0826 nmol/L. [
conclusions[
Indexed as
Identifiers
39725695What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.